Multicenter, open-label, single dose study to evaluate

Project: Research project

Description

Multicenter, open-label, single dose study to evaluate safety, tolerability and pharmacokinetics of LCZ696 followed by a 52-week randomized, double-blind, parallel group, active-controlled study to evaluate
StatusActive
Effective start/end date1/1/169/30/21

Funding

  • NOVARTIS PHARMACEUTICALS CORPORATION

Fingerprint

Pharmacokinetics
Safety
LCZ 696